Literature DB >> 16632549

Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture).

Michel Félétou1, Paul M Vanhoutte.   

Abstract

Endothelial cells synthesize and release various factors that regulate angiogenesis, inflammatory responses, hemostasis, as well as vascular tone and permeability. Endothelial dysfunction has been associated with a number of pathophysiological processes. Oxidative stress appears to be a common denominator underlying endothelial dysfunction in cardiovascular diseases. However, depending on the pathology, the vascular bed studied, the stimulant, and additional factors such as age, sex, salt intake, cholesterolemia, glycemia, and hyperhomocysteinemia, the mechanisms underlying the endothelial dysfunction can be markedly different. A reduced bioavailability of nitric oxide (NO), an alteration in the production of prostanoids, including prostacyclin, thromboxane A2, and/or isoprostanes, an impairment of endothelium-dependent hyperpolarization, as well as an increased release of endothelin-1, can individually or in association contribute to endothelial dysfunction. Therapeutic interventions do not necessarily restore a proper endothelial function and, when they do, may improve only part of these variables.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16632549     DOI: 10.1152/ajpheart.00292.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  237 in total

Review 1.  Vascular effects of the red blood cell storage lesion.

Authors:  John D Roback
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.

Authors:  Michel Félétou; Ralf Köhler; Paul M Vanhoutte
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

3.  Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Pharmacol Res       Date:  2011-09-14       Impact factor: 7.658

4.  Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim.

Authors:  Rui-jun Zhao; Hai Wang
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

5.  Adaptive response of vascular endothelial cells to an acute increase in shear stress magnitude.

Authors:  Ji Zhang; Morton H Friedman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

Review 6.  Vasoconstrictor prostanoids.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-03-24       Impact factor: 3.657

Review 7.  Endothelial dysfunction in diabetes: multiple targets for treatment.

Authors:  Hong Ding; Chris R Triggle
Journal:  Pflugers Arch       Date:  2010-03-18       Impact factor: 3.657

8.  KCa 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS.

Authors:  Serge Simonet; Marc Isabelle; Mélanie Bousquenaud; Nicolas Clavreul; Michel Félétou; Christine Vayssettes-Courchay; Tony J Verbeuren
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

9.  Specific cell-derived microvesicles: Linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women.

Authors:  Virginia M Miller; Brian D Lahr; Kent R Bailey; Howard N Hodis; Sharon L Mulvagh; Muthuvel Jayachandran
Journal:  Atherosclerosis       Date:  2015-12-28       Impact factor: 5.162

10.  Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats.

Authors:  Y Alvarez; A M Briones; R Hernanz; J V Pérez-Girón; M J Alonso; M Salaices
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.